Compare CODA & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CODA | ADCT |
|---|---|---|
| Founded | 1994 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.7M | 136.1M |
| IPO Year | 2007 | 2019 |
| Metric | CODA | ADCT |
|---|---|---|
| Price | $10.87 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 97.7K | ★ 1.5M |
| Earning Date | 06-15-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 15.62 | ★ 30.86 |
| EPS | ★ 0.36 | N/A |
| Revenue | $20,316,161.00 | ★ $81,357,000.00 |
| Revenue This Year | $18.28 | N/A |
| Revenue Next Year | $12.62 | $66.49 |
| P/E Ratio | $29.94 | ★ N/A |
| Revenue Growth | 4.98 | ★ 14.85 |
| 52 Week Low | $7.80 | $0.78 |
| 52 Week High | $18.00 | $4.98 |
| Indicator | CODA | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 64.16 | 46.52 |
| Support Level | $10.85 | $0.98 |
| Resistance Level | $12.24 | $1.20 |
| Average True Range (ATR) | 0.38 | 0.09 |
| MACD | 0.09 | -0.01 |
| Stochastic Oscillator | 76.62 | 25.00 |
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company operates in three distinct business segments: the Marine Technology business, Acoustic Sensors and Material Business and the Defense Engineering Services Business. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).